Loss of CDKN2A remodels Golgi morphology to create a lipid peroxidation vulnerability

Loss of the tumor suppressor CDKN2A/p16 occurs in ~50% of human cancers, yet no therapies specifically target tumors with complete loss or reduced CDKN2A/p16 expression (hereafter CDKN2A/p16-Low). Identifying selective vulnerabilities in CDKN2A/p16-Low tumors therefore represents a critical unmet need. Here, we identify altered Golgi morphology as a vulnerability in CDKN2A/p16-Low melanoma. A CRISPR knockout screen revealed that genes associated with Golgi membranes are essential for CDKN2A/p16-Low cell survival. CDKN2A/p16 knockdown in human and murine cancer cells was associated with striking Golgi compaction. CDKN2A/p16 knockdown sensitized cells to pharmacologic Golgi disruption via lipid peroxidation both in vitro and in vivo. Notably, reduced Retinoblastoma-associated protein (RB1) expression did not recapitulate the increased sensitivity to Golgi disruption, supporting a role for non-canonical p16 functions in this vulnerability. Together, these findings uncover a previously unrecognized link between CDKN2A/p16-Low status and Golgi remodeling, revealing a Golgi-associated metabolic vulnerability in CDKN2A/p16-Low melanomas.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.765755
Primary Topic
Cellular transport and secretion
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Loss of CDKN2A remodels Golgi morphology to create a lipid peroxidation vulnerability

Amandine Amalric, Andrew V. Kossenkov, Apoorva Uboveja, Aidan R. Cole et al.
bioRxiv (Cold Spring Harbor Laboratory)
Cellular transport and secretion
preprint

Loss of CDKN2A remodels Golgi morphology to create a lipid peroxidation vulnerability

Amandine Amalric, Andrew V. Kossenkov, Apoorva Uboveja, Aidan R. Cole, Katherine M. Aird, Raquel Buj, Baixue Yang, Nathaniel W. Snyder, Andrea Andress Huacachino, Ruiying Zheng, Alex Tom, Qin Liu, Rebecca Scarpati
preprint en

Abstract

Loss of the tumor suppressor CDKN2A/p16 occurs in ~50% of human cancers, yet no therapies specifically target tumors with complete loss or reduced CDKN2A/p16 expression (hereafter CDKN2A/p16-Low). Identifying selective vulnerabilities in CDKN2A/p16-Low tumors therefore represents a critical unmet need. Here, we identify altered Golgi morphology as a vulnerability in CDKN2A/p16-Low melanoma. A CRISPR knockout screen revealed that genes associated with Golgi membranes are essential for CDKN2A/p16-Low cell survival. CDKN2A/p16 knockdown in human and murine cancer cells was associated with striking Golgi compaction. CDKN2A/p16 knockdown sensitized cells to pharmacologic Golgi disruption via lipid peroxidation both in vitro and in vivo. Notably, reduced Retinoblastoma-associated protein (RB1) expression did not recapitulate the increased sensitivity to Golgi disruption, supporting a role for non-canonical p16 functions in this vulnerability. Together, these findings uncover a previously unrecognized link between CDKN2A/p16-Low status and Golgi remodeling, revealing a Golgi-associated metabolic vulnerability in CDKN2A/p16-Low melanomas.

bioRxiv (Cold Spring Harbor Laboratory)
The Wistar Institute (US), Fred and Pamela Buffett Cancer Center (US), University of Nebraska Medical Center (US), Temple University (US)
Good health and well-being
Cellular transport and secretion
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon